Clinical evaluation of NK211 and CDDP for cervical cancer.
Phase 1
- Conditions
- Advanced and/or recurrent cervical cancer.
- Registration Number
- JPRN-jRCT2080221794
- Lead Sponsor
- ippon Kayaku Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- Female
- Target Recruitment
- Not specified
Inclusion Criteria
Patients must have recurrent, persistent or stage 4B cervical cancer for which standard curative surgery and/or radiation therapy do not exist or are no longer effective, etc.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Incidence and severity (grade) of the adverse event/toxicity (drug related AE)<br>CTCAE Ver.4.03-JCOG
- Secondary Outcome Measures
Name Time Method Antitumor effect<br>RECIST Ver1.1